Glympse Bio
Cambridge
About Glympse Bio
Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $93.3M
- Funding stage: M&A
- Last round: Series Unknown (Dec 2021)
- Website: glympsebio.com
- Phone: 617-863-3636
Industries & Categories
Biotechnology, Health Care, Life Science, Medical Device, Nanotechnology
Social Profiles
Canonical: https://fsome.com/organization/glympse-bio-3923 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.